...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BJU international >The role of transarterial embolization in the treatment of renal cell carcinoma.
【24h】

The role of transarterial embolization in the treatment of renal cell carcinoma.

机译：经动脉栓塞在肾细胞癌治疗中的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To review the role of transarterial renal embolization in our unit, assessing the indications, tolerability and efficacy of this technique for treating renal cell carcinoma (RCC). PATIENTS AND METHODS: Thirty patients undergoing transarterial embolization between 1991 and 1999 were identified and 25 case notes analysed retrospectively. RESULTS: Most patients (14 of 25) presented with less advanced (stage I-III) RCC who were unable or unwilling to undergo radical surgery; the remainder (11) presented with advanced (stage IV) disease. The embolizing agent was ethanol, usually combined with stainless steel coils (85% of cases). Procedural pain and fever was controlled successfully. The median hospital stay associated with the procedure was 4 days. At the time of analysis six of 11 stage IV and 11 of 14 stage I-III patients were alive (median follow-up 27 and 39 months, respectively). Symptoms from the primary tumour were well controlled. Overall, 17 of 25 (68%) of patients reported no problems while three (12%) required brief hospital admission for treatment of persistent haematuria. Fourteen patients were subsequently re-staged; the primary tumour in two had increased, in seven remained unchanged and in five it decreased. No patients without metastases developed them and metastases in two patients regressed. CONCLUSION: Transarterial embolization is associated with minimal morbidity and complications, and subsequent symptom control is good. The effect of palliative embolization on RCC progression is unknown and requires prospective investigation. Presently, there is no role for cytoreductive embolization; it should be included as a treatment option in clinical trials evaluating such options in patients with metastatic RCC.
机译：目的：回顾经动脉肾栓塞术在我们单位中的作用，评估该技术治疗肾细胞癌（RCC）的适应症，耐受性和疗效。病人与方法：确定1991年至1999年间30例经动脉栓塞的患者，并回顾性分析25例病例。结果：大多数患者（25名中的14名）表现出较弱的（I-III期）RCC，他们不能或不愿接受根治性手术。其余（11）患者患有晚期（IV期）疾病。栓塞剂是乙醇，通常与不锈钢卷结合使用（85％的情况）。程序性疼痛和发烧得到了成功控制。与该手术相关的中位住院时间为4天。在分析时，11名IV期患者中有6名和14名I-III期患者中的11名还活着（中位随访时间分别为27个月和39个月）。来自原发肿瘤的症状得到了很好的控制。总体而言，在25名患者中，有17名（68％）没有问题，而三名（12％）患者需要短暂入院治疗持续性血尿。随后有十四名患者被重新分期。原发肿瘤中有2例增加，7例未改变，5例减少。没有转移的患者均未发生转移，并且有两名患者的转移消退。结论：经动脉栓塞术的发病率和并发症最少，且随后的症状控制良好。姑息栓塞对RCC进展的影响尚不清楚，需要进行前瞻性研究。目前，细胞减少栓塞尚无作用。在评估转移性RCC患者的治疗方案的临床试验中，应将其作为治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号